Bifunctional PROTACs for EGFR Mutation Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR-targeting PROTACs fail to effectively degrade all main EGFR mutations, such as Del19, L858R, Del19/T790M, L858R/T790M, Del19/T790M/C797S, and L858R/T790M/C797S, limiting their therapeutic efficacy in overcoming drug resistance in non-small cell lung cancer.
Innovation Solution
Development of novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase ligands, which recruit targeted proteins to E3 ubiquitin ligase for degradation, enhancing the ability to target and degrade these resistant EGFR mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current EGFR-targeting PROTACs are used, then degradation of wild-type EGFR is achieved, but degradation of resistant EGFR mutations (Del19, L858R, T790M, C797S) is insufficient
Solution Approach 1:
The patent applies universality by designing PROTAC molecules with EGFR inhibitors that can bind to multiple EGFR mutation types (wild-type, L858R, T790M, C797S, and combination mutations) through a single compound. The bifunctional PROTAC structure enables one molecule to target diverse EGFR variants, achieving broad-spectrum degradation efficacy across different mutation profiles.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of EGFR inhibitor moieties within the PROTAC molecules to optimize binding affinity across different EGFR mutations. By adjusting inhibitor parameters (chemical groups, linkers) and E3 ligase ligand parameters, the patent achieves enhanced degradation efficacy for resistant mutations while maintaining selectivity.
2Reliability
If traditional EGFR inhibitors are used, then enzymatic activity inhibition is achieved, but protein degradation is not accomplished
Solution Approach 1:
The patent applies the intermediary principle by introducing E3 ubiquitin ligase as a mediator in the PROTAC molecule. The E3 ligase ligand moiety recruits E3 ligase to the target EGFR protein, facilitating ubiquitination and subsequent proteasomal degradation. This intermediary mechanism transforms simple inhibition into active protein degradation, achieving the desired productivity improvement.
Solution Approach 2:
The patent replaces the mechanical inhibition mechanism (blocking active site) with a biochemical degradation mechanism (ubiquitin-proteasome pathway). Instead of merely inhibiting EGFR enzymatic activity through competitive binding, the PROTAC induces covalent modification (ubiquitination) that targets the protein for degradation, substituting the inhibition mechanism with a more potent degradation mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel bifunctional compounds demonstrate improved efficacy in degrading a broader range of EGFR mutations, potentially overcoming resistance obstacles in non-small cell lung cancer treatment.
Implementation Method 1
recruitment of the E3 ligase to the specific unwanted proteins results in ubiquitination and subsequent degradation of the target protein by the proteasome
Implementation Method 2
ubiquitination and subsequent degradation of the target protein by the proteasome. The whole process of ubiquitination and proteasomal degradation is known as the ubiquitin-proteasome pathway (UPP)
Implementation Method 3
Immunomodulatory drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, function as monovalent promoters of PPIs by binding to the cereblon (CRBN) subunit of the CRL4ACRBN E3 ligase complex and recruiting neosubstrate proteins
Data Source
AI summary
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.